JP2014526883A5 - - Google Patents

Download PDF

Info

Publication number
JP2014526883A5
JP2014526883A5 JP2014517181A JP2014517181A JP2014526883A5 JP 2014526883 A5 JP2014526883 A5 JP 2014526883A5 JP 2014517181 A JP2014517181 A JP 2014517181A JP 2014517181 A JP2014517181 A JP 2014517181A JP 2014526883 A5 JP2014526883 A5 JP 2014526883A5
Authority
JP
Japan
Prior art keywords
virus
seq
gene
recombinant
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517181A
Other languages
English (en)
Japanese (ja)
Other versions
JP6253576B2 (ja
JP2014526883A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/043606 external-priority patent/WO2012177924A2/en
Publication of JP2014526883A publication Critical patent/JP2014526883A/ja
Publication of JP2014526883A5 publication Critical patent/JP2014526883A5/ja
Application granted granted Critical
Publication of JP6253576B2 publication Critical patent/JP6253576B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517181A 2011-06-24 2012-06-21 インフルエンザウイルス変異体およびその使用 Expired - Fee Related JP6253576B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161501034P 2011-06-24 2011-06-24
US61/501,034 2011-06-24
PCT/US2012/043606 WO2012177924A2 (en) 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2017227944A Division JP6496000B2 (ja) 2011-06-24 2017-11-28 インフルエンザウイルス変異体およびその使用
JP2017227945A Division JP6445662B2 (ja) 2011-06-24 2017-11-28 インフルエンザウイルス変異体およびその使用

Publications (3)

Publication Number Publication Date
JP2014526883A JP2014526883A (ja) 2014-10-09
JP2014526883A5 true JP2014526883A5 (https=) 2015-08-06
JP6253576B2 JP6253576B2 (ja) 2017-12-27

Family

ID=47423213

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2014517181A Expired - Fee Related JP6253576B2 (ja) 2011-06-24 2012-06-21 インフルエンザウイルス変異体およびその使用
JP2017227944A Active JP6496000B2 (ja) 2011-06-24 2017-11-28 インフルエンザウイルス変異体およびその使用
JP2017227945A Expired - Fee Related JP6445662B2 (ja) 2011-06-24 2017-11-28 インフルエンザウイルス変異体およびその使用
JP2019041172A Active JP6870017B2 (ja) 2011-06-24 2019-03-07 インフルエンザウイルス変異体およびその使用
JP2021068472A Active JP7231666B2 (ja) 2011-06-24 2021-04-14 インフルエンザウイルス変異体およびその使用
JP2023022678A Pending JP2023071764A (ja) 2011-06-24 2023-02-16 インフルエンザウイルス変異体およびその使用
JP2025002842A Pending JP2025066111A (ja) 2011-06-24 2025-01-08 インフルエンザウイルス変異体およびその使用

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2017227944A Active JP6496000B2 (ja) 2011-06-24 2017-11-28 インフルエンザウイルス変異体およびその使用
JP2017227945A Expired - Fee Related JP6445662B2 (ja) 2011-06-24 2017-11-28 インフルエンザウイルス変異体およびその使用
JP2019041172A Active JP6870017B2 (ja) 2011-06-24 2019-03-07 インフルエンザウイルス変異体およびその使用
JP2021068472A Active JP7231666B2 (ja) 2011-06-24 2021-04-14 インフルエンザウイルス変異体およびその使用
JP2023022678A Pending JP2023071764A (ja) 2011-06-24 2023-02-16 インフルエンザウイルス変異体およびその使用
JP2025002842A Pending JP2025066111A (ja) 2011-06-24 2025-01-08 インフルエンザウイルス変異体およびその使用

Country Status (11)

Country Link
US (7) US9284533B2 (https=)
EP (3) EP4023749A1 (https=)
JP (7) JP6253576B2 (https=)
KR (7) KR102080061B1 (https=)
CN (3) CN103781901B (https=)
AU (5) AU2012272837B2 (https=)
CA (4) CA3055006C (https=)
DK (2) DK2723855T3 (https=)
ES (1) ES2890427T3 (https=)
MX (4) MX383065B (https=)
WO (1) WO2012177924A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3169427B2 (ja) 1992-04-07 2001-05-28 新日本製鐵株式会社 磁気特性の優れた二方向性珪素鋼板の製造方法
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2493912B1 (en) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
WO2011160024A2 (en) 2010-06-17 2011-12-22 Fuzians Biomedicals, Inc. Compounds useful as antiviral agents, compositions, and methods of use
KR102080061B1 (ko) * 2011-06-24 2020-02-21 플루젠, 인코퍼레이티드 인플루엔자 바이러스 돌연변이체들 및 그들의 용도들
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型pb2遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
CN104056276B (zh) * 2013-03-20 2017-05-10 上海生物制品研究所有限责任公司 一种流感病毒减毒活疫苗及其制备方法
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
WO2015142671A2 (en) 2014-03-17 2015-09-24 Flugen, Inc. Influenza virus vectors and uses therefor
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
CA3054584A1 (en) * 2017-02-27 2018-08-30 Flugen, Inc. Influenza b virus mutants and uses therefor
KR102785815B1 (ko) 2017-02-27 2025-03-24 플루젠, 인코퍼레이티드 인플루엔자에 대한 면역원성 조성물
CN107151659B (zh) * 2017-03-01 2021-04-02 苏州系统医学研究所 一种流感病毒株及其应用
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン(ha)タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
KR102370100B1 (ko) * 2019-02-15 2022-03-07 아이디바이오 주식회사 이종 인플루엔자 a 바이러스에 대한 면역/치료반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 유전자 전달체 및 치료백신
US11214799B2 (en) * 2019-03-12 2022-01-04 The University Court Of The University Of Edinburg Old College HA-specific influenza virus attenuated vaccine comprising mutations in segment 7, and uses therefor
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
JP7756911B2 (ja) * 2019-06-07 2025-10-21 フルゲン, インコーポレイテッド インフルエンザウイルスバックボーン
CN110468130B (zh) * 2019-08-09 2021-08-06 中国人民解放军军事科学院军事医学研究院 流感长链非编码RNA-lnc330及其应用
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたnaを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
EP4185601A4 (en) 2020-07-21 2024-10-30 Flugen, Inc. SKELETON OF THE INFLUENZA VIRUS
CA3186408A1 (en) * 2020-07-21 2022-01-27 Michael J. Moser Vaccine using m2/bm2-deficient influenza vectors
CN114381439B (zh) * 2022-01-27 2023-12-15 浙江迪福润丝生物科技有限公司 一种同义突变结合删除突变的流感病毒的致弱方法及致弱流感病毒株和应用
CN114438043B (zh) * 2022-01-27 2023-12-15 浙江迪福润丝生物科技有限公司 一种区分感染和免疫的致弱流感病毒疫苗株及疫苗
CN114381440B (zh) * 2022-01-27 2023-12-15 浙江迪福润丝生物科技有限公司 一组基于同义突变和/或缺失突变的a型流感病毒致弱毒株及其制备方法和应用
CN114410681B (zh) * 2022-01-27 2024-02-13 浙江迪福润丝生物科技有限公司 一种基于m基因核苷酸片段删除的流感病毒的致弱方法以及致弱流感病毒株和应用
CN114381438B (zh) * 2022-01-27 2024-02-02 浙江迪福润丝生物科技有限公司 一种流感病毒的致弱方法及流感致弱病毒株和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6253576U (https=) 1985-09-21 1987-04-02
JPH05515Y2 (https=) 1987-12-16 1993-01-08
AU5698798A (en) * 1996-12-20 1998-07-17 Procter & Gamble Company, The A dry laid structure comprising particulate material
GB9815040D0 (en) * 1998-07-10 1998-09-09 Medical Res Council Conditional mutant
JP4927290B2 (ja) * 2000-04-14 2012-05-09 ウィスコンシン アルムニ リサーチ ファンデイション 変異イオンチャンネルタンパク質を含んで成るウイルス
US7176021B2 (en) 2001-02-23 2007-02-13 Wisconsin Alumni Research Foundation Mutant cells with altered sialic acid
AU2004232992A1 (en) * 2003-04-23 2004-11-04 Wisconsin Alumni Research Foundation Recombinant influenza viruses holding a mutation in a transmembrane protein gene
CA2525953C (en) * 2003-05-28 2023-10-10 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
US8961477B2 (en) * 2003-08-25 2015-02-24 3M Innovative Properties Company Delivery of immune response modifier compounds
CN1810961B (zh) * 2006-02-22 2010-05-12 中国人民解放军军事医学科学院微生物流行病研究所 一种重组流感病毒及其制备方法与应用
US9474798B2 (en) * 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
JP4932940B2 (ja) * 2007-11-12 2012-05-16 セラクローン サイエンシーズ, インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
EP2296701A1 (en) 2008-06-11 2011-03-23 Flugen, Inc. Cell-based systems for producing influenza vaccines
US20100061995A1 (en) * 2008-09-08 2010-03-11 Damian Michael Carragher Immunotherapy To Treat Or Prevent Viral Infection
EP2424980A1 (en) 2009-05-01 2012-03-07 Redbiotec AG Recombinant virus-like particles encoded by multi-gene vector
US20110172638A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including multi-functional cover
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
US20110172639A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Device and method for delivery of microneedle to desired depth within the skin
US20110172645A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Wearable drug delivery device including integrated pumping and activation elements
US20110172637A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including tissue support structure
US8668675B2 (en) 2010-11-03 2014-03-11 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
TW201303143A (zh) 2011-03-22 2013-01-16 Exxonmobil Upstream Res Co 低排放渦輪機系統中用於攫取二氧化碳及產生動力的系統與方法
KR102080061B1 (ko) * 2011-06-24 2020-02-21 플루젠, 인코퍼레이티드 인플루엔자 바이러스 돌연변이체들 및 그들의 용도들
JP6639334B2 (ja) 2016-06-20 2020-02-05 株式会社日立製作所 業務処理フロー生成システム、生成方法および装置
JP6120237B1 (ja) 2016-06-20 2017-04-26 仁博 平嶋 サービスシステム、アプリケーションプログラム及び決済方法

Similar Documents

Publication Publication Date Title
JP2014526883A5 (https=)
Chen et al. Advances in development and application of influenza vaccines
Auladell et al. Recalling the future: immunological memory toward unpredictable influenza viruses
Wong et al. Traditional and new influenza vaccines
Chroboczek et al. Virus-like particles as vaccine.
Metz et al. Effective chikungunya virus-like particle vaccine produced in insect cells
CN109477074B (zh) 用于疫苗开发的改进的乙型流感病毒复制
Park et al. Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2
EP2493912B1 (en) High titer recombinant influenza viruses with enhanced replication in vero cells
Acosta-Coley et al. Vaccines platforms and COVID-19: what you need to know
JP7627911B2 (ja) 卵内複製のための安定化されたhaを持つ組換えインフルエンザウイルス
WO2021150874A1 (en) Recombinant influenza viruses with stabilized na
Ahata et al. CCHFV vaccine development, current challenges, limitations, and future directions
JP2021536228A (ja) ヘマグルチニン(ha)タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
US20230310583A1 (en) Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof
Petro-Turnquist et al. Swine influenza A virus: challenges and novel vaccine strategies
Yu et al. Recent research advances in the development of Dabie Banda virus vaccines
McMurry et al. A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A
Luo et al. Virus-like particles containing a prefusion-stabilized F protein induce a balanced immune response and confer protection against respiratory syncytial virus infection in mice
Yang et al. Progress in African swine fever vector vaccine development
Sircy et al. Generation of antigen-specific memory CD4 T cells by heterologous immunization enhances the magnitude of the germinal center response upon influenza infection
Zhao et al. Adjuvant-free, self− assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses
US20230398200A1 (en) Modified chikungunya viruses and sindbis viruses and uses thereof
Di et al. The self-assembled nanoparticle-based multi-epitope influenza mRNA vaccine elicits protective immunity against H1N1 and B influenza viruses in mice
Yuan et al. Advancements in the application and research of baculovirus vector vaccines for respiratory diseases in human